Germany approves new new coronavirus vaccine clinical trial
-
Last Update: 2020-07-11
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Paul Ehrlich Institute announced the same day, the trial of the candidate vaccine developed by the German "healing" vaccine company, is a mRNA (messenger rnaycanic acid) vaccineIts mechanism is to encode the new coronavirus sting protein messenger RNA into human cells, let the cells synthesize the virus antics protein, thereby inducing the human immune response, so that when the human body comes into contact with the real virus has an immunityAccording to the, 168 healthy volunteers participated in the first phase of the clinical trial, 144 of whom will be vaccinatedThe trial process will gradually increase the dose to confirm the general safety and tolerance of the vaccine, as well as the appropriate dose to induce the human immune responsePaul Ehrlich Institute announced on April 22nd that it had approved Germany's first clinical trial of a new coronavirus vaccine, developed by the German bio-new technology company, and is also a mRNA vaccineGermany will conduct more clinical trials of vaccines in the coming months, the institute said, and that more than one vaccine product will be needed to combat the new crown outbreak to ensure adequate supply"healing" vaccine company is currently the focus of German and EU funded vaccine research and development enterprisesThe German government has announced plans to invest 300 million euros in a "cure" vaccine company to accelerate the development of its new vaccine and treatment program.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.